Drug Profile
LBS 007
Alternative Names: LBS-007Latest Information Update: 31 Jan 2024
Price :
$50
*
At a glance
- Originator Columbia University Medical Center; Memorial Sloan-Kettering Cancer Center
- Developer Columbia University Medical Center; Lin Bioscience; Memorial Sloan-Kettering Cancer Center
- Class Antineoplastics
- Mechanism of Action CDC7 protein kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Acute myeloid leukaemia
- Preclinical Haematological malignancies; Solid tumours
Most Recent Events
- 09 Dec 2023 Pharmacodynamics data from a preclinical trial in Acute myeloid leukaemia presented at the 65th American Society of Hematology Annual Meeting and Exposition 2023 (ASH-Hem-2023)
- 20 Jul 2023 Phase-I/II clinical trials in Acute myeloid leukaemia in Australia (unspecified route) (NCT05756322)
- 09 Mar 2023 Preclinical development is ongoing in USA (Lin Bioscience pipeline, March 2023)